A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

FDA Commissioner Dr. Marty Makary said Thursday that the United States needs to transform its health care approach from ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy ...

Covid vaccines from Pfizer and Moderna must carry expanded warning labels informing patients of the risk of rare heart inflammation. The FDA is also cracking down on off-brand GLP-1 drugs. Other ...

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

News last week that a CNN investigative report found dozens of fake podcasts on the popular audio streaming and media service platform Spotify, illegally ...

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a ...

Using Sernova Biotherapeutics' investigational Cell Pouch Bio-hybrid Organ, transplanted human donor islet cells helped ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.